RxDoctor Payments Data

Viswatej Avutu, MD

Medical Oncology · New York, NYNPI 1255759163

Payments from drug & device makers

$243,977in general payments, 2019–2025

Across 3 payments — averaging $81,326 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$240K
  • EMD Serono, Inc.$4K
  • BTG International Inc.$57

What the payments were for

  • Consulting fees$3,80099%
  • Food & beverage$571%

General payments by program year

22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$240,120
EMD Serono, Inc.1$3,800
BTG International Inc.1$57

How this compares

$243,977 in reported general payments places this provider in the 55th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York

Medicare billing

Part B allowed, 2024
$44,815
Medicare patients
83
Services billed
376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Imatinib Mesylate46$91,969
Ondansetron Hcl12$224

Paid to pharmacies, not to this prescriber.

Other medical oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →